Also, it implies the need for research of novel treatment strategies, such as the tyrosine kinase inhibitors (TKIs) targeting angiogenic kinases, mTOR-inhibitors in PIK3CA mutated cancers, or immunotherapy with checkpoint inhibitors in PD-L1 positive cancers [5]. This evidence concerns the gene CD274 and cancer.